Comments on: India Grants First Compulsory Licence, For Bayer Cancer Drug

By: mirada sustentable » 22º Concurso Internacional de Pintura de Niños sobre el Ambiente

Mon, 21 Jan 2013 00:50:22 +0000

[...] de enfermedades, algo que afortunadamente ya está cobrando luz en la justicia como el caso de esta droga para el cáncer que se transformó en una causa nacional para el gobierno de la India que hizo posible que el [...]

By: Dr Aparna

Dr Aparna — Tue, 08 Jan 2013 02:46:30 +0000

Please keep me updated on this topic

By: Most-Read IP-Watch Stories Of 2012: India Pharma, Europe, ACTA, WIPO Technical Assistance, Gene Patents | Intellectual Property Watch

Sun, 30 Dec 2012 16:26:52 +0000

[...] India Grants First Compulsory Licence, For Bayer Cancer Drug http://www.ip-watch.org/2012/03/12/india-grants-first-compulsory-licence-for-bayer-cancer-drug/ [...]

By: Hard Times Ahead For Rights Holders? IPR High On Brussels Agenda Before Recess | Intellectual Property Watch

Fri, 13 Jul 2012 12:08:17 +0000

[...] Office to grant a first compulsory licence on the “Sorafenib tosylate” drug patent by Bayer (IPW, Public Health, 12 March 2012). Parts of that decision had raised “alarm bells” in both the US and the EU administration, [...]

By: Novartis’ Indian Patent Law Challenge Postponed Again | Intellectual Property Watch

Fri, 06 Jul 2012 17:24:06 +0000

[...] appeal against India’s grant of a compulsory licence on Bayer anti-cancer drug Nexavar drug (IPW, Public Health, 12 March 2012) is scheduled to be heard on 21 August before the Intellectual Property Appellate Board in Chennai, [...]